Competitive: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus London, United Kingdom

Competitive: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus Cambridge, United Kingdom

Competitive: The Institute Of Cancer Research: Key Information Salary: £41,607* to £48,224 Dependent on relevant Postdoctoral experience. Future progression is based on annual performance review. London, United Kingdom

Competitive: BenevolentAI: We are looking for a talented Senior Bioinformatics Data Scientist to join the Product & Tech division. You will work in a cross-functional team apply London, United Kingdom

£48,788 - £56,747 : 37 hours per week: Public Health Scotland: An exciting opportunity has arisen within the Clinical and Protecting Health Directorate of PHS Edinburgh/Glasgow

£38,082 - £45,622: Barts Cancer Institute , Queen Mary University London: About the Role The Postdoctoral research Assistant will join the teams led by Dr Rouault-Pierre & Dr Ana Rio-Machin (Nat Com 2015, 2019, 2020; Cell S London, United Kingdom

Competitive: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus Cambridge, United Kingdom

Funding Opportunity PAR-25-192 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Notice NOT-CA-25-012 from the NIH Guide for Grants and Contracts

Notice NOT-HL-24-034 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-193 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Funding Opportunity PA-25-163 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

Funding Opportunity PA-25-245 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

£37,472 - £45,622 per annum: Barts Cancer Institute , Queen Mary University London: About the Role A fully funded Postdoctoral Research Assistant position is available to join a team led by Prof Susana Godinho to study how amplified London, United Kingdom

Funding Opportunity PAR-25-134 from the NIH Guide for Grants and Contracts. The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutionsis to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F and A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information.

Notice NOT-MH-25-095 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-285 from the NIH Guide for Grants and Contracts. This R61/R33 concept complements NIMHs suite of clinical trial NOFOs by supporting feasibility and infrastructure development (R61) followed by well-powered clinical trials (R33) to test the effectiveness of system interventions and strategies for improving the organization, delivery, coordination, and clinical and functional outcomes of mental health services. System interventions - which may span, for example, structural, policy, organizational, and interpersonal domains - attend to issues about the access, equity, engagement/utilization, value (cost/financing), management, or quality and safety of mental health services, with the goal of improved care processes and clinical and functional outcomes. Accordingly, the focus of system interventions may include a variety of care settings, such as health systems and organizations, mental health and community clinics, schools, and child welfare or juvenile justice systems

Funding Opportunity PAR-25-184 from the NIH Guide for Grants and Contracts. NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Funding Opportunity PAR-25-183 from the NIH Guide for Grants and Contracts. NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Funding Opportunity PAR-25-182 from the NIH Guide for Grants and Contracts. Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this NOFO encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to two years of support for evaluation of target engagement and establishment of intervention parameters, and up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).